09:43 AM EST, 12/13/2024 (MT Newswires) -- AbbVie ( ABBV ) said Friday that it has agreed to buy Nimble Therapeutics.

AbbVie ( ABBV ) said the deal includes Nimble's lead asset, an investigational drug in preclinical development to treat psoriasis, as well as a pipeline of other drug candidates for autoimmune diseases.

AbbVie ( ABBV ) said it will also acquire Nimble's peptide synthesis, screening, and optimization platform, which is used to identify peptide candidates for several targets.

AbbVie ( ABBV ) said it will pay $200 million at closing for the company, plus some interim funding payments. Nimble's shareholders remain eligible for a potential payment if a development milestone is met, AbbVie ( ABBV ) added.

Price: 173.94, Change: +0.75, Percent Change: +0.43